- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Leslie Citrome on Coverage of Metabolic-Friendly Antipsychotics
Leslie Citrome, MD, MPH, of New York Medical College, discusses payer coverage of atypical antipsychotics with fewer metabolic side effects.
Leslie Citrome, MD, MPH, of New York Medical College, discusses payer coverage of atypical antipsychotics with fewer metabolic side effects.
Transcript
What is the landscape like for patients trying to get coverage for atypical antipsychotis that cause fewer metabolic side effects?
We do have choices in terms of the array of antipsychotics that are available for the treatment of schizophrenia. Some may be more metabolically friendly than others. But they tend to be branded products, and so more costly. But it's not usually an impossibility to get them for our patients. I don't see huge obstacles in prescribing branded, atypical antipsychotics where they would be needed.
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
